Jena, Germany | 04 March 2010 | ZEISS Group
With effect from the end of today’s Annual General Meeting, Dr. Ludwin Monz is the new CEO of Carl Zeiss Meditec AG and as announced on 18 January follows Dr. Michael Kaschke, who resumes as Chairman of the company’s Supervisory Board
Dr. Ludwin Monz is the new CEO of Carl Zeiss Meditec. He takes over from Dr. Michael Kaschke. At today’s Annual General Meeting, Kaschke was elected back to the Supervisory Board and was appointed its Chairman in the subsequent Supervisory Board meeting.
“I am looking forward to the new task and will continue the path the company has taken towards sustainable growth”, explains Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG, continuing: “Customer-oriented innovation, excellent service and expansion into new markets as part of our corporate RACE programme are clearly the three most important strategic initiatives for the coming months.”
Dr. Ludwin Monz has been a member of Carl Zeiss Meditec AG’s Management Board since October 2007 and is responsible for the largest strategic business unit, Ophthalmological Systems. Prior to this he headed up the Microsurgery strategic business unit for over six years. During this time he developed this department into a growing and highly profitable part of the company. Numerous innovative products were launched on the market under his leadership. With a doctorate in physics and an MBA, Monz joined the Carl Zeiss Group in 1994 and has worked in medical technology since 2000. In addition to various R&D positions, Dr. Ludwin Monz has worked in numerous key roles within the Group.
“Having Dr. Ludwin Monz as our new CEO has allowed us to win a successor known for innovation and growth from our own ranks. With ten years of expertise in medical technology he knows the company, its customers and their needs and Carl Zeiss Meditec’s energy and potential. I know that Carl Zeiss Meditec is in excellent hands with its current Management Board team and look forward to supporting the company again in the future as Supervisory Board Chairman”, says Dr. Michael Kaschke, Supervisory Board Chairman of Carl Zeiss Meditec AG.
The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and optoelectronic industries that generates revenues totaling around EUR 2.1 billion (2008/09).
Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions and Lifestyle Products. The company develops and distributes surgical microscopes, diagnostic systems for ophthalmology, microscopes, lithography optics, industrial measuring technology, planetarium technology, optronic products, camera and cine lenses, and binoculars and spotting scopes. The eyeglass business is bundled in the joint venture Carl Zeiss Vision International GmbH.
The Carl Zeiss Group has approximately 13,000 employees, including more than 8,000 in Germany. The Carl Zeiss business groups hold leading positions in their markets.
Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials.
The company creates innovative visualisation solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy.
In the 2008/2009 (30 September) financial year the approx. 2,100 employees generated revenue of approximately € 640 million. The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France.
Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". The head office of Carl Zeiss AG is in Oberkochen, Germany. In financial year 2008/2009 (balance sheet date: 30 September) the Group generated revenue of around € 2.1 billion. Carl Zeiss employs almost 13,000 staff, over 8,000 thereof in Germany.
Further information at www.zeiss.com